fda tirzepatide compound update confirms shortage is still over, gives compounders a grace period FDA Update: Current Guidelines for

Systemic safety considerations Retatrutide carries several safety considerations regardless of administration route

Discontinuation typically leads to appetite return and weight regain within 3-6 months

Phelouzat MA, Laforge T, Arbogast A, Quadri RA, Boutet S, Proust JJ

G., & Della Ma Plentz, R

Clinical studies suggest that it can reduce the risk of major adverse cardiovascular events, including heart attacks and strokes, particularly in individuals with type 2 diabetes who are at high risk for these conditions

they are reshaping how people think about what they eat, how much they eat and what they are willing to pay for it